Lipocine Inc.
LPCN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LPCN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LPCN
Lipocine Inc. is a specialty pharmaceutical company focused on developing oral prodrug-based therapies for central nervous system (CNS) disorders, including postpartum depression and major depressive disorder, as well as other therapeutic areas such as essential tremor, epilepsy, and obesity management.
Key risk: Need for additional capital
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Lipocine Inc..
Lipocine Inc. is a specialty pharmaceutical company focused on developing oral prodrug-based therapies for central nervous system (CNS) disorders, including postpartum depression and major depressive disorder, as well as other therapeutic areas such as essential tremor, epilepsy, and obesity management.
- Lipocine's lead clinical candidate is LPCN 1154 for postpartum depression (PPD), with additional pipeline programs including LPCN 2201 for major depressive disorder (MDD), LPCN 2203 for essential tremor, LPCN 2101 for epilepsy, and LPCN 2401 for improved body composition in obesity management [sec_mda · as of 2026-08-04].
- The company reported cash and equivalents of $5.0M as of June 30, 2026, with total revenue of $0.2M and a net loss of -$2.6M for the period [sec].
- Lipocine expects its existing capital resources to fund projected operating requirements through at least August 4, 2027, but acknowledges the need to raise additional capital to support ongoing and future clinical development activities [sec_mda · as of 2026-08-04].
- The company has out-licensed TLANDO for territories outside the U.S., South Korea, the GCC, and Brazil, and is seeking partnerships for other assets including LPCN 1148 for decompensated cirrhosis and LPCN 1107 for preterm birth prevention [sec_mda · as of 2026-08-04].
- Lipocine has incurred operating losses in most years since inception and expects to continue incurring losses as it advances its clinical pipeline [sec_mda · as of 2026-05-07].
What works
- Lipocine has a diversified pipeline of oral prodrug candidates targeting multiple CNS and metabolic indications, which may reduce single-program risk [sec_mda · as of 2026-08-04].
- The company has established ex-U.S. commercialization partnerships for TLANDO, with partners planning to file marketing approval applications in Canada, GCC countries, South Korea, and Brazil [sec_mda · as of 2026-05-07].
- Lipocine's cash runway is projected to extend through at least August 4, 2027, providing a buffer for ongoing development activities [sec_mda · as of 2026-08-04].
What to weigh
- Lipocine has a history of operating losses and expects to continue incurring losses as it advances its clinical pipeline, with no approved products generating revenue [sec_mda · as of 2026-05-07].
- The company will need to raise additional capital to support its operations and clinical trials, and there is no guarantee that such financing will be available on favorable terms [sec_mda · as of 2026-08-04].
- All of Lipocine's product candidates are in early-to-mid stages of development, with significant regulatory and clinical risks that could affect timelines and costs [sec_mda · as of 2026-08-04].
From the filings
Quoted directly from source documents.
Lipocine's pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2203 for essential tremor, LPCN 2101 for epilepsy, and LPCN 2401 for obesity management.
“depression ("PPD"); LPCN 2201 for major depressive disorder ("MDD"); LPCN 2203 for essential tremor; LPCN 2101 for epilepsy; LPCN 2401 for improved body composition in obesity management.”
SEC MD&A · August 4, 2026
Lipocine expects its existing capital to fund operations through at least August 4, 2027.
“We believe that our existing capital resources, together with interest thereon, will be sufficient to meet our projected operating requirements through at least August 4, 2027”
SEC MD&A · August 4, 2026
Lipocine has incurred operating losses in most years since inception and expects to continue.
“We have incurred operating losses in most years since our inception and we expect to continue to incur operating losses into the foreseeable future”
SEC MD&A · May 7, 2026
Lipocine's ex-U.S. partners are planning to file marketing approval applications in multiple territories.
“our other ex-U.S. commercialization partners are planning to file marketing approval applications in one or more of the GCC countries, South Korea and Brazil in 2025 and/or 2026.”
SEC MD&A · November 6, 2025
Risks & what to watch (3)›
Key risks
- Need for additional capital — Lipocine will need to raise additional capital to support operations and clinical trials; failure to do so may limit its ability to continue as a going concern [sec_mda · as of 2026-05-07].
- Clinical and regulatory uncertainty — All product candidates are in early-to-mid stage development; outcomes of clinical trials and regulatory actions are uncertain and could significantly alter costs and timelines [sec_mda · as of 2026-08-04].
- History of operating losses — Lipocine has incurred operating losses in most years since inception and expects to continue, with no approved products generating revenue [sec_mda · as of 2026-05-07].
What to watch
- Regulatory and clinical progress of lead candidate LPCN 1154 for postpartum depression [sec_mda · as of 2026-08-04].
- Marketing approval filings by ex-U.S. partners for TLANDO in Canada, GCC countries, South Korea, and Brazil [sec_mda · as of 2025-11-06].
- Ability to secure additional financing or partnerships to extend cash runway beyond August 2027 [sec_mda · as of 2026-08-04].
- Initiation and results of clinical trials for pipeline candidates LPCN 2201, LPCN 2203, LPCN 2101, and LPCN 2401 [sec_mda · as of 2026-08-04].
Sources: SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Lipocine Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lipocine Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
22.3 months
D/E 0.10 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
4 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$12.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 401,336 | $3.2M |
| stempoint capital lp | 320,840 | $2.6M |
| boothbay fund management, llc | 140,487 | $1.1M |
| blackrock, inc. | 89,272 | $713K |
| geode capital management, llc | 63,135 | $505K |
| exome asset management llc | 60,861 | $486K |
| diadema partners lp | 50,000 | $400K |
| j. goldman & co lp | 42,170 | $337K |
| renaissance technologies llc | 38,497 | $308K |
| two sigma investments, lp | 33,750 | $270K |
Showing top 10 of 39 institutional holders of Lipocine Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 2.0%
- Days to cover
- 1.4
- Shares short
- 143,656
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LPCN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lipocine Inc.?
Lipocine Inc. is a specialty pharmaceutical company focused on developing oral prodrug-based therapies for central nervous system (CNS) disorders, including postpartum depression and major depressive disorder, as well as other therapeutic areas such as essential tremor, epilepsy, and obesity management.
Who is the CEO of Lipocine Inc.?
Dr. Mahesh V. Patel Ph.D. is the chief executive officer of Lipocine Inc. (LPCN).
Where is Lipocine Inc. headquartered?
Lipocine Inc. (LPCN) is headquartered in Salt Lake City, UT, United States.
What therapeutic areas does Lipocine Inc. focus on?
Lipocine Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.